Evidence map›Paper›PMID 39802290›Full record

ArticleAnnals of gastroenterology

Simethicone with or without N-acetylcysteine as premedication in esophagogastroduodenoscopy: a systematic review and meta-analysis.

Caroline Tanadi, Fegita Beatrix Pajala, Yehuda Tri Nugroho Supranoto, Kevin Tandarto, Maureen Miracle Stella, Randy Adiwinata, Paulus Simadibrata, Marcellus Simadibrata

Abstract read
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Caroline TanadiSchool of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia (Caroline Tanadi, Fegita Beatrix Pajala, Maureen Miracle Stella).
Fegita Beatrix PajalaSchool of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia (Caroline Tanadi, Fegita Beatrix Pajala, Maureen Miracle Stella).
Yehuda Tri Nugroho SupranotoBioinformatics Research Center, Indonesian Institute of Bioinformatics (INBIO-INDONESIA), Malang (Yehuda Tri Nugroho Supranoto).
Kevin TandartoIntensive Care Unit, Columbia Asia Hospital, Semarang (Kevin Tandarto).
Maureen Miracle StellaSchool of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia (Caroline Tanadi, Fegita Beatrix Pajala, Maureen Miracle Stella).
Randy AdiwinataGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta (Randy Adiwinata Paulus Simadibrata).
Paulus SimadibrataGastrointestinal Cancer Center, MRCCC Siloam Hospital Semanggi, Jakarta (Randy Adiwinata Paulus Simadibrata).
Marcellus SimadibrataDivision of Gastroenterology, Pancreatobiliary and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta (Marcellus Simadibrata), Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The impairment of gastrointestinal mucosa visibility during esophagogastroduodenoscopy (EGD), due to the presence of foam and bubbles, may lead to reduced quality in the EGD results. The combination of simethicone, a defoaming agent, along with N-acetylcysteine (NAC), which has mucolytic properties, has been proposed to improve the visibility of the mucosa. This study aimed to evaluate the effectiveness of pre-procedural administration of simethicone and N-acetylcysteine in improving mucosal visibility, procedure time and mucosal cleansing volume needed during EGD. Methods: We conducted a comprehensive literature search from inception to November 23, 2023, in PubMed, CENTRAL, ProQuest, SAGE, and JSTOR. We included randomized clinical trials that investigated the effects of simethicone with or without NAC as premedication in EGD. For the quantitative analysis, standardized mean difference (SMD) was used to assess continuous outcomes and risk ratio for dichotomous outcomes. The Cochrane risk of bias 2 tool was used to evaluate the risk of bias. Results: This meta-analysis comprised a total of 20 studies and found that simethicone with or without NAC improved mucosal visibility compared with control (SMD -1.27, 95% confidence interval [CI] -1.74 to -0.81, P<0.001). The combination of simethicone and NAC was significantly better than simethicone alone (SMD -0.68, 95%CI -1.08 to -0.28, P=0.001). Simethicone with or without NAC also shortened the procedure time compared to control (MD -1.40, 95%CI -2.67 to -0.12, P=0.03). The risk of bias was low with a moderate grade of certainty. Conclusion: The administration of simethicone with or without NAC may improve EGD quality.

Indexed as

esophagogastroduodenoscopymeta-analysisN-acetylcysteinepremedicationSimethicone

Identifiers

PMID39802290
PMCPMC11724382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.